Effects of plasmalogen on mood and performance in university athletes

INTERVENTION: Ingestion of 4 capsules per day of either plasmalogen (0.5 mg per capsule) or placebo for a period of 4 weeks. CONDITION: Healthy persons PRIMARY OUTCOME: T score of the total distrubance of mood (TDM) score of the Profile of Mood State (POMS2). SECONDARY OUTCOME: 1) seven scales of POMS2;; 2) Athene Insomnia Scale;; 3) brain fatigue measurements including Brain‐Fatigue Score Questionnaire and Kraepeline test;; 4) exercise performance including VO2max, muscle strength, and power;; 5) plasmalogens in plasma and erythrocytes;; 6) blood concentrations of brain derived neurotrophic factor (BDNF) and adiponectin;; 7) urinaruy 8‐hydroxy deoxy quanine (8‐OHdG);; 8) body mass index and percent fat;; 9) daily variation of mental and physical condition assessed by a smartphone application; and; 10) 24‐hour heart rate variation (those with a specified consent only). INCLUSION CRITERIA: To meet all of the three conditions: 1) male students belonging to sport clubs of Kyushu Sangyo University; 2) unmarried men aged 18‐22 years at the time of provision of informed consent; and 3) those who are able to provide wriiten informed consent.